Mainz Biomed NV

MYNZ

Company Profile

  • Business description

    Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

  • Contact

    Robert Koch Strasse 50
    Sirius Gutenberg Park
    MainzRP55129
    DEU

    T: +49 61315542860

    https://www.mainzbiomed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    26

Stocks News & Analysis

stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks

Nvidia: Back in business in China; Raising fair value estimate

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,816.4058.90-0.66%
CAC 407,742.0524.16-0.31%
DAX 4024,077.1016.810.07%
Dow JONES (US)43,906.96116.33-0.26%
FTSE 1008,946.017.690.09%
HKSE24,517.7672.36-0.29%
NASDAQ20,602.5975.21-0.36%
Nikkei 22539,663.4014.62-0.04%
NZX 50 Index12,754.5964.960.51%
S&P 5006,224.0919.67-0.32%
S&P/ASX 2008,561.8068.50-0.79%
SSE Composite Index3,503.781.22-0.03%

Market Movers